A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Inclusion Criteria: 1. Age of ≥ 18 years old; 2. ECOG PS score of 0 or 1; 3. Pathologically diagnosed as prostate adenocarcinoma; 4. High-risk patients 5. No distant metastasis (clinical staging of M0) as determined by BICR of imaging examinations; 6. Subjects who are candidates for and plan to undergo radical prostatectomy (removal of the entire prostate and seminal vesicle plus pelvic lymphadenectomy); Exclusion Criteria: 1. Subjects who received any prior treatment for prostate cancer, except medical ADT and/or first-generation androgen receptor antagonists (such as bicalutamide) for not more than 4 weeks; 2. Subjects who received any other investigational products or underwent major surgery within 4 weeks prior to randomization; 3. Subjects who are planning bilateral orchidectomy during the treatment period of the study; 4. Subjects with dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption; 5. Subjects with a history of epilepsy, or diseases that can induce seizures occurred within 12 months prior to randomization (including a history of transient ischemic attack, stroke, traumatic brain injury, and cognitive impairment, requiring hospitalization); 6. Subjects with active heart disease within 6 months prior to randomization, including: severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring medical treatment;